May 25, 2023
2 min watch
Save
VIDEO: Encapsulated cell therapy shows efficacy in treatment of macular telangiectasia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Key takeaways:
- A novel encapsulated cell therapy shows efficacy in the treatment of macular telangiectasia.
- This could provide long-term treatment of macular telangiectasia and potentially other diseases.
SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Jim Mazzo and Rich Small, CEO of Neurotech Pharmaceuticals, present a novel encapsulated cell therapy for long-term treatment of macular telangiectasia.
Phase 3 studies have shown positive results. Explantation after more than a decade has shown that the device is intact, and cells are viable and healthy.
“In my 44 years, this is one of the most novel technologies I have ever seen,” Mazzo said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Mazzo reports being the executive chairman of Neurotech Pharmaceuticals. Small reports being the CEO of Neurotech Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.